Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
2023-07-18 03:01:56 ET Orexo AB press release ( OTCQX:ORXOY ): Q2 GAAP EPS of -SEK 0.37. Revenue of SEK 157.7 million (+6.7% Y/Y). Positive EBITDA of SEK 5.6 million in Q2 (SEK -32.5 million Q2, 2022, and SEK -41.1 million Q1, 2023). Cash flow from operating ...
Orexo Q2 2023 Interim Report PR Newswire UPPSALA, Sweden , July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total net revenues of SEK 157.7 m (147.8) › &...
Orexo wins patent litigation for ZUBSOLV® in the US PR Newswire The court found Orexo´s patents valid and infringed by Sun The outcome once again confirms the strength of the company´s intellectual property rights and the ability to develop innovative p...
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22 nd are now available for online viewing. REGISTER NOW AT : https://...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGIST...
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124 PR Newswire UPPSALA, Sweden , April 3, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue med...
Orexo publishes the Annual and Sustainability Report for 2022 PR Newswire UPPSALA, Sweden , March 28, 2023 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com , where it is also avai...
Orexo postpones publication of the Annual Report PR Newswire UPPSALA, Sweden , March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023 . The previou...
Orexo ( OTCQX:ORXOY ) said it submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of nasal rescue medication for opioid overdose, OX124. OX124, is based on Orexo's drug delivery platform amorphOX and contains a high-dose of naloxone,...
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose PR Newswire OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US invol...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20 th , 2024. This event is co-sponsored by Zack’s Small Cap Research. ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm PR Newswire UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024 , Orexo AB (publ), ("Orexo" or the " Company ") (STO: ORX) (OTCQX: ORXOY) succ...